Stay updated on Trastuzumab Emtansine in Chinese HER2+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Trastuzumab Emtansine in Chinese HER2+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Trastuzumab Emtansine in Chinese HER2+ Breast Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.
    Difference
    1.0%
    Check dated 2025-07-04T00:22:33.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.8%
    Check dated 2025-06-19T13:28:55.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-12T08:39:41.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    The web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T05:35:46.000Z thumbnail image
  6. Check
    70 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T06:17:50.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    The page has removed detailed information about a Phase III clinical study for trastuzumab emtansine in breast cancer, including participant criteria and study design, while adding a new version number and a reference to breast cancer.
    Difference
    24%
    Check dated 2025-04-15T20:39:51.000Z thumbnail image

Stay in the know with updates to Trastuzumab Emtansine in Chinese HER2+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Trastuzumab Emtansine in Chinese HER2+ Breast Cancer Clinical Trial page.